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ABSTRACT
Deep learning has demonstrated success in health risk prediction es-
pecially for patients with chronic and progressing conditions. Most
existing works focus on learning disease patterns from longitudinal
patient data, but pay little attention to the disease progression stage
itself. To fill the gap, we propose a Stage-aware neural Network
(StageNet) model to extract disease stage information from patient
data and integrate it into risk prediction. StageNet is enabled by (1)
a stage-aware long short-termmemory (LSTM)module that extracts
health stage variations unsupervisedly; (2) a stage-adaptive con-
volutional module that incorporates stage-related progression pat-
terns into risk prediction. We evaluate StageNet on two real-world
datasets and show that StageNet outperforms state-of-the-art mod-
els in risk prediction task and patient subtyping task. Compared
to the best baseline model, StageNet achieves up to 12% higher
AUPRC for risk prediction task on two real-world patient datasets.
StageNet also achieves over 58% higher Calinski-Harabasz score
(a cluster quality metric) for a patient subtyping task.
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1 INTRODUCTION
Deep learning has demonstrated early successes in health risk pre-
diction using electronic health records (EHR) data especially for
patients with chronic and progressing conditions such as heart
diseases and Parkinson’s disease [2, 4, 16, 26]. Most existing works
focus on the extraction of disease patterns by modeling the rela-
tionship between disease progression and time from longitudinal
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patient data. For example, Pham et al. [29] utilized RNN and a mul-
tiscale pooling layer to integrate temporal disease patterns from
different time scales. Baytas et al. [2] and Ma et al. [26] simulates
progression of patients’ status by using temporal information to
decay the information from historical timesteps.
Despite these successes, the aforementioned works [2, 26, 29, 43]
implicitly assume that disease progression is smooth in time — the
longer the time is, the greater the change of health status will be.
However, in reality, disease progression speed can vary significantly
depending on the underlying disease stage.
Motivating example: Fig. 1 plots the variation of albumin and
hypersensitive C-reactive protein (hs-CRP) of an end-stage renal
disease (ESRD) patient. We can observe the patient’s health status
between t1 and t2 is different from the rest time period. The sudden
decline of albumin and fluctuation of hs-CRP indicate the patient’s
status is deteriorating rapidly. We consider the patient’s health
condition enters a new stage at t1. The disease stage here refers to
a time period with consistent status progression. It is not specific
to a single disease (e.g. Alzheimer’s Stage 1 or 2) but considers
generally all comorbidities a patient has. For example, deteriorating
and recovering are two different stages.
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Figure 1: The change of biomarkers during different stages
of an ESRD patient
Challenges: Disease progression stages indicate different risk lev-
els. However, we still have the following challenges to utilize stage
information in risk prediction tasks.
(1) How to extract disease progression stages from com-
plex EHR data? Although important disease stage infor-
mation is often unavailable in data and sometimes not even
clearly defined for many diseases. Many temporal models
such as LSTM have gating mechanism to control what histor-
ical information to remember or forget. However, the explicit
underlying stage or change point is not clearly specified by
those models.
(2) How to leverage disease progression stage information
for more accurate risk prediction? Intuitively disease
progression patterns should be similar within one stage
but different across stages, as shown in Fig. 1(b). Probably
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due to the absence of stage information in the data, disease
stage information is largely ignored in predictive modeling
of EHR data. Since the progression patterns relate to health
risks [13, 31], the model should learn to extract and select in-
formative patterns from each disease stage for more accurate
risk prediction.
Contributions: To address these challenges, we propose a new
Stage-aware neural Network model (StageNet) to extract disease
stage information from patient data and integrate it into risk pre-
diction. StageNet consists of two modules, a stage-aware LSTM
module and a stage-adaptive convolutional module. Our StageNet
model is enabled by the following technical contributions.
(1) Extract disease progression stage without supervision.
The stage-aware LSTM module of StageNet can capture the
stage variation of patients’ health conditions unsupervisedly.
Specifically, we integrate inter-visit time information into
LSTM cell states, which enables each dimension in the cell
state to decide the storage proportion between long-term
progression and short-term health status information. With
such a design, StageNet can evaluate the variation of patient
health conditions compared with previous stages.
(2) Learn disease progression patterns from disease stage
information. StageNet further incorporates extracted dis-
ease progression stage information into the convolution op-
eration, which can learn progression patterns closely related
to the current stage. We further re-calibrate these patterns
to emphasize informative patterns for outcome prediction.
We evaluated StageNet with both health risk prediction task
and patient subtyping task on real-world urgent care MIMIC-III
dataset and end-stage renal disease dataset. Risk prediction results
show that StageNet consistently outperforms all state-of-the-art
models on both datasets in terms of different evaluation metrics.
The improvement of StageNet is up to 12% in AUPRC compared
to the best baseline model. The patient subtyping results show
that StageNet performs better than baseline models in identifying
discriminative patient subgroups.
2 RELATEDWORK
Disease Progression Modeling Recent years, various deep learn-
ing models have been proposed to model disease progression. One
solution is to model the disease trajectory using Markov-based
models. For example, Sukkar et al. [36] applied Hidden Markov
Model (HMM) to learn AlzheimerâĂŹs disease progression. Wang
et al. [40] proposed a probabilistic model to learn a continuous-time
disease progression. Liu et al. [25] developed a continuous time
HMM for modeling glaucoma and Alzheimer patients. However,
these works assume Markov property which might not be true in
practice when existing long term dependency.
Instead of modeling state transition probability, another line of
efforts, to which our approach belongs, focus on utilizing patients’
general health status progression to conduct clinical prediction
tasks such as subtyping [2, 10] or risk prediction [30, 43]. For ex-
ample, T-LSTM [2] incorporated the elapsed time information into
the standard LSTM architecture to model status progression in the
presence of time irregularities. Health-ATM [26] used a time-aware
convolutional layer by integrating time stamps into the original
convolutional layer to model status progression. However, none of
these works model disease progression from the stage perspective.
To the best of our knowledge, we are the first work to explicitly
extract disease stage progression information and utilize it in risk
prediction tasks.
Attention mechanism for feature re-calibration Feature re-
calibration refers to using attention mechanism to emphasize in-
formative input features or convolutional feature maps and sup-
press less informative ones. Feature re-calibration mechanism has
achieved success in computer vision tasks. Hu et al. [17] proposed
Squeeze-and-Excitation Block to explicitly model the dependencies
between the channels of convolutional features by aggregating
convolutional feature maps across spatial dimensions. In EHR anal-
ysis, feature re-calibration mechanism is mainly used to provide
model interpretability. For example, Choi et al. proposed RETAIN to
provide feature interpretability using attention over input features.
In this work, we re-calibrate disease progression patterns via
extracting the progression theme at the current stage. Our model
can adaptively emphasize most indicative features to help better
predict patients’ health risks at different stages.
Other related work: The underlying model of the stage-aware
LSTM module in our work is related to the ordered neuron mecha-
nism in [33], which proposes to solve NLP parsing tasks. However,
unlike word sequences, the time irregularity in EHR data has clini-
cal meanings. In this work, the inter-visit time intervals are used
to help LSTM summarize stages of patients’ status progression.
3 STAGENETMETHOD
3.1 Overview
Below we define the data and task studied in this work and provide
the list of notations used in StageNet in Table. 1.
Definition 1 (Patient Records). In longitudinal EHR data, each
patient can be represented as a sequence of multivariate observa-
tions P = [v1,v2, ...,vT ], where T is the number of visits of the
patient. Each visit record vt ∈ RNv is a concatenation of clinical
features (i.e., lab tests and measurements) including multi-hot and
numerical values, where Nv is the number of medical features at
each visit. To model the time irregularity of visits, we also use
T = [∆1,∆2, ...,∆t ] to represent the elapsed time between two
visits, ∆1 = 0, specifically.
Problem 1 (Health Risk prediction). Given a patient’s visit
records P , we define dynamic patient risk prediction as to pre-
dict the health risk yˆt ∈ {0, 1} at the t-th timestep, which indicates
the target outcome of interest (e.g., mortality, decompensation).
As shown in Figure 2, StageNet comprises three modules: (1)
a stage-aware LSTM module, (2) a stage-adaptive convolutional
module, and (3) a prediction module. StageNet takes patient EHR
sequence P and time interval sequenceT as input of the stage-aware
LSTM module, and output the t-th time hidden state ht along with
stage variation factor st . Here st represents the variation degree
at the t-th visit compared to historical status – a large st indicat-
ing a higher chance of entering a new stage. We feed ht and st to
the stage-adaptive convolutional module to extract patients’ status
progression patterns within an observation window K . The length
of observation window K is similar to convolutional kernel size,
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Table 1: Notation definition
Notation Definition
P ;T patient record sequence; time interval sequence
vt ∈ RNv multivariate visit record at the t-th visit
∆t time interval betweenvt andvt−1
yt ground truth of prediction targets at the t-th visit
yˆt predictions at the t-th visit
ht ∈ RNh hidden state of LSTM at the t-th timestep
ct ∈ RNh cell state of LSTM at the t-th timestep
ut ∈ RNm extracted progression patterns within the current stage
zt ∈ RNh status progression theme at the current stage
xt ∈ RNm re-calibration weights of progression patterns
u˜t ∈ RNm re-calibrated stage-adaptive progression patterns
st stage variation at the t-th timestep
∆sti stage variation from ht−K+i to ht
f˜t ; i˜t master forget gate; master input gate
vt Δt
ht
Stage-adaptive Convolutional Module
yt
Output Layer
…
ztStage progression theme
SA-LSTM Cell
vt-k Δt-k
SA-LSTM Cell
v1 Δ1
SA-LSTM Cell
stht-k st-k …
…
Stage-aware LSTM Module
Figure 2: StageNet model: at the t-th timestep, the stage-
aware LSTM takes current visit vt and elapsed time ∆t as
input to calculate current hidden state ht and current stage
variation st . Then the hidden states in the observation win-
dowK will be fed into the stage-adaptive convolutionalmod-
ule. The convolutional module will extract progression pat-
terns at the current stage and re-calibrate these patterns us-
ing the progression theme zt . Then the module will use re-
calibrated patterns to predict health risk yˆt .
which decides the timescale of extracted convolutional patterns.
The stage information st is integrated to convolution operations
to extract disease progression patterns that closely related to the
current stage. We re-calibrate these patterns to emphasize infor-
mative patterns and suppress less useful ones via extracting the
disease progression theme zt at the current stage. Last, we predict
the health risk yˆt based on these improved patient representations.
3.2 Stage-aware LSTM module
LSTM background Given a sequence of patient health records P
and a sequence of inter-visit time intervalsT , our goal is to infer
the stage variation of the patient’s health status (i.e., st ) while
constructing current health status (i.e., ht ). Original LSTM consists
of forget gate ft , input gate it and output gate ot . At the t-th
timestep, the original LSTM takes previous hidden state ht−1, cell
state ct−1 and current visitvt as input, and output current hidden
stateht and cell state ct . However, cell state ct does not differentiate
where the historical information is from (whether is from recent
past or long history). StageNet will use two new gates to make
different dimensions in the cell state indicate different time scales.
Goal The key objective is to differentiate historical information in
the cell state. If we can differentiate recent and old history in ct ,
we can determine whether the change to ct is due to old history
or recent history. Then a change mainly due to the recent history
means the underlying disease stage has just changed. Hence, we
can derive the disease stage change based on the change to the cell
state.
Idea The idea is to make each dimension in the cell state repre-
sent patientsâĂŹ status at a different time scale. Intuitively, the
dimensions in cell state ct can be divided into the low-ranking
part (the first half of ct ) and the high-ranking part (the second
half of ct ). The low-ranking part contains short-term health status
information that only recent visits. And high-ranking part contains
patients’ long-term progression information that will last several
visits or even the entire visit sequence. Note that because the low-
ranking part is related to most recent visits, the update frequency
of low-ranking dimensions is always higher than high-ranking di-
mensions. One simple way to enforce low and high ranking parts
is to use two separate binary mask vectors. The low-ranking mask
vector can be [1, . . . , 1, 0, . . . , 0], while the high-ranking mask will
be [0, . . . , 0, 1, . . . , 1].
Soft masking Instead of hard binary masks, we learn two soft
mask vectors:
• f˜t for high-ranking part (representing old history);
• i˜t for low-ranking part (representing recent history).
In particular, the ranking is dynamically determined using informa-
tion from patients’ current visitvt and historical health statusht−1,
adjusted by the elapsed time ∆t between two visits. We utilize and
further extend the master forget gate f˜t and master input gate i˜t
in [33] by using time interval information as follows:
p f˜ = so f tmax(Wf˜ (vt ⊕ ∆t ) + Uf˜ (ht−1 ⊕ ∆t ) + bf˜ )
pi˜ = so f tmax(Wi˜ (vt ⊕ ∆t ) + Ui˜ (ht−1 ⊕ ∆t ) + bi˜ )
f˜t =
→cm (p f˜ )
i˜t =
←cm (p f˜ )
(1)
where b is the bias, cm denotes the cumulative sum, the arrow above
cm indicates the direction of cumulative sum and ⊕ denotes the
concatenation operation. p f˜ and pi˜ correspond to the probabilistic
distribution of dimensions of ct for high-ranking (old history) and
low-ranking (recent history), respectively. Following the properties
of the cm operation, the values in f˜t are monotonically increasing
from 0 to 1 (e.g. {0.2, 0.4, 0.8, 1}), and those in i˜t are monotonically
decreasing from 1 to 0 (e.g. {1, 0.8, 0.4, 0.2}). Hence, f˜t and i˜t can
be used to serve as the soft mask for high-ranking part and low-
ranking part, respectively.
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Cell state updateWe define the new calculation for current cell
state ct as:
cˆt =tanh(Wcvt +Ucht−1 + bc )
wt = f˜t ⊙ i˜t
ct =wt ⊙ (ft ⊙ ct−1 + it ⊙ cˆt )
+ ( f˜t −wt ) ⊙ ct−1 + (i˜t −wt ) ⊙ cˆt
ht =ot ⊙ tanh(ct )
(2)
where the calculation of intermediate cell state cˆt and hidden state
ht are same with the original LSTM. Values in f˜t are used to decide
which dimensions in ct to store long-term information about status
progression (i.e. ct−1), and values in i˜t decide which dimensions
to store short-term information (i.e. cˆt ). In Eq. 2,wt decide which
dimensions to store the overlap part between ct−1 and cˆt . Besides
the overlapping information, the independent (non-overlapping)
information in ct−1 and cˆt are stored into ct based on the values of
( f˜t −wt ) and (i˜t −wt ), respectively. Fig 3 shows the structure of
stage-aware LSTM.
Stage progression variation Since values in f˜t decide where to
store progression information, we denote st as:
st = arдmax(p f˜ ) (3)
The value of st decides howmuch history information is used to cal-
culate the current ct . If st is large, there is almost no historical state
information in current cell state, which means that the patient’s
current health status have changed a lot compared to history status.
In other word, a large st may indicate that the patient’s status may
have entered a new stage.
Sincearдmax function is non-differentiable, we use the following
equation to estimate st :
st ≈
Nh∑
i=1
i × p f˜ (i) = Nh (1 −
1
Nh
Nh∑
i=1
f˜t (i)) + 1 (4)
where f˜t (i) and p f˜ (i) are the i-th values in f˜t and p f˜ .
Example illustration We use a toy example to better illustrate
how i˜t and f˜t store patients’ health status at different timescales
and summarize stage variation factor st . Assume Nh = 5, pi˜ =
[0, 0, 0, 1, 0] and p f˜ = [0, 0, 1, 0, 0]. According to Eq. 1 and 2, f˜t =
[0, 0, 1, 1, 1], i˜t = [1, 1, 1, 1, 0] andwt = [0, 0, 1, 1, 0]. And st = 2. st
indicates the variation of patients’ stage.
The ct is calculated as:
ct =[0, 0, 1, 1, 0] ⊙ (ft ⊙ ct−1 + it ⊙ cˆt )
+ [0, 0, 0, 0, 1] ⊙ ct−1 + [1, 1, 0, 0, 0] ⊙ cˆt (5)
The fifth dimension in ct is used to store long-term progression
information from ct−1, and the first and second dimensions are
used to store short-term health status from cˆt . The third and fourth
dimensions are used to store overlapping information. However,
because we use so f tmax activation, the actual values in f˜t and i˜t
are decimals instead of 0 and 1.
As f˜t and i˜t only focus on coarse-grained control, in practice,
we reduce the dimension of f˜t and i˜t to Nm = Nh/C similar to
[33], where C is a chunk size factor. Therefore, every dimension
vt Δt
𝒉𝒉𝒕𝒕
𝒄𝒄𝒕𝒕
st ht
𝒉𝒉𝒕𝒕−𝟏𝟏
𝒄𝒄𝒕𝒕−𝟏𝟏
Figure 3: The structure of stage-aware LSTM cell
within each C-sized chunk shares the same master gates. A smaller
C can make the model describe patients’ status variation in more
details.
3.3 Stage-adaptive convolutional module
To leverage the stage information learned from LSTM, we develop
a stage-adaptive convolutional module on top of the recurrent layer
to extract and re-calibrate patient health progression patterns for
risk prediction.
Progression patterns of patients’ health status are critical in
predicting patients’ risks [13, 42]. Since there are many medical
research indicate that these progression patterns are often similar
within one stage, but vary across different stages [13, 31, 42], we
expect StageNet can extract patterns that are closely related to
patients’ current stage using convolutional filters. We also design
the model to adaptively select the most informative patterns for
risk prediction at the current stage. We achieve this through three
steps: 1) learning stage progression patterns 2) extracting progression
theme at the current stage and 3) re-calibrating progression patterns.
The structure of stage-adaptive convolutional module is shown in
Fig. 4.
Learning stage progression patterns: We further extract the
progression patterns of at the current stage by using stage-weighted
convolution operators. We modify the original CNN by integrating
disease stage information into the convolution operation.
Mathematically, at the t-th time, we calculate the distance be-
tween stages of historical visits within the observation window and
the stage of current visit as:
∆st = softmax(−→cm (st−K , ..., st )) (6)
where K is the length of observation window. The length of ob-
servation window K is similar to convolutional kernel size, which
decides the timescale of extracted progression patterns. The values
in ∆st are monotonically decreasing from 1 to 0. We denote the i-th
value in ∆st as ∆sti . A large ∆s
t
i indicates that the stage of ht−K+i
is far from the current stage of ht .
In stage-weighted convolution operation at the t-th timestep, the
convolutional module takes concatenated historical hidden states
sequence of LSTM (i.e. ht−K :t = [ht−K , ...,ht ]) as input. Different
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Figure 4: Stage-adaptive convolutional module: The mod-
ule takes historical hidden state ht and stage variation st
within the observation window K as input, and learn pro-
gression patterns ut using stage-weighted convolution op-
eration. These patterns are re-calibrated to emphasise the
most informative patterns at the current stage via extract-
ing the current progression theme zt .
from the original convolutional layer, the weights of input variables
are re-weighted by their stage distance ∆sti in each convolution
computation as:
uit =mi ∗ ht−K :t =
Nh∑
j=1
mji ∗ (h
j
t−K :t ⊙ ∆st ) (7)
where ∗ is the convolution operation,mc = [m1c , ...,mNhc ], uit ∈
RK−S+1.mji is a 1D convolution kernel representing a single chan-
nel ofmi that acts on the corresponding channel of ht−K :t and
S is the kernel size. We use multiple kernels to generate extract
different patterns, and the number of kernels is Nm . We concate-
nate the output of kernels to get the final convolution output as
ut = [u1t , ...,uNmt ]. We set S = K to make each kernel can extract
progression patterns that represent the whole stage, so that the
final dimension is ut ∈ RNm .
In Eq. 7, The weights of patients’ historical health status are
adjusted according to the distance of stages ∆st in order to extract
patterns that are closely related to the current stage. If the stage of
a historical status is far from the current stage, it will have a lower
weight in the stage-weighted convolution operation and vice versa.
Extracting progression theme at the current stage: Since the
output of the convolution operation ut is the concatenation of
multiple patterns extracted by different kernels. The importance of
these patterns may vary and depends on patients’ status at different
stages. In order to select themost informative patterns at the current
stage, we should provide the model with a global view of patients’
status at the current stage as:
zt =
1
K
K∑
i=0
∆sti ht−K+i (8)
The global status representation at the current stage zt is the
weighted average of hidden states within the observation window.
zt can be regarded as the progression theme of the current stage.
The importance of different temporal patterns will be calculated
based on this theme.
Re-calibrating progression patterns: After obtaining the status
progression theme at the current stage, we map the reprensentation
zt to an importance vector xt , where the i-th value in xt indicates
the importance of the i-th extracted temporal pattern in ut . xt is
calculated as:
xt = σ (Wx1δ (Wx2zt )) (9)
where σ refers to the sigmoid functon, δ is the ReLU function,
Wx2 ∈ RNx×Nm andWx1 ∈ RNm×Nx . We use two fully-connected
(FC) layers to map the progression theme zt to xt , i.e. a dimension-
ality-reduction layer with ReLU activation to compress the repre-
sentation while capturing the non-linearity, and a dimensionality-
increasing layer to rescale the output to the original dimension of
ut . We use sigmoid activation to generate the importance weights
between 0 and 1.
Finally, the features in ut is re-calibrated using xt as:
u˜t = ut ⊙ xt (10)
The re-calibration mechanism can be regarded as a channel-wise
attention mechanism like [17]. However, the attention weights (i.e.
the importance of each pattern) is calculated by patients’ status pro-
gression theme at the current stage instead of using global average
pooling to generate channel-wise statistics in [17] or calculating
alignment between historical states.
3.4 Prediction module
The prediction layer takes the output of stage-adaptive convolu-
tional module as input, and outputs a binary label yˆt , which indi-
cates the patient’s current health risk. Note that, we include residue
connections between the convolutional module and the output
layer. In order to achieve this, we set Nm = Nh . We compute yˆt as:
yˆt = σ (Wy (u˜t + ht ) + by ) (11)
whereWy ∈ RNh . We choose the cross-entropy function to calcu-
late the loss for each patient as:
L = − 1
T
T∑
t=1
(y⊤t log(yˆt ) + (1 − yt )⊤ log(1 − yˆt )) (12)
We use the Adam algorithm [22] for optimization. We summarize
StageNet algorithm below.
4 EXPERIMENT
We evaluated StageNet model by comparing against other base-
lines on public dataset MIMIC-III and ESRD (i.e., end-stage renal
disease) dataset. The code is provided in 1.
4.1 Dataset description
We use the following data to evaluate our model.
• MIMIC-III DatasetWe use Intensive Care Unit (ICU) data
from the publicly available Medical Information Mart for
Intensive Care (MIMIC-III) database [20]. Following the work
[15], the cohort of 33, 678 unique patients with a total of
1https://github.com/v1xerunt/StageNet
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Algorithm 1 The StageNet model
Input:
Patient records P = [v1,v2, ...,vT ], time interval sequenceT =
[∆1,∆2, ...,∆t ] and the length of observation window K .
Training:
Initialize h0 and c0 to zero.
for i = 1 to T do
Input last hi−1 and ci−1 to stage-aware LSTM cell;
Obtain hi , ci and si via Eq. 1 and 2;
Compute ∆i via Eq. 6;
Compute progression patterns ui via Eq. 7;
Calculate current stage progression theme zi via Eq. 8;
Compute re-calibrated patterns u˜i using Eq. 10;
Compute current predicted risk yˆi via Eq. 11;
end for
Update the model’s parameters by optimizing the loss in Eq. 12.
2,202,114 samples (i.e., records) is used. The raw data includes
17 physiologic variables at each visit, which is transformed
into a 76-dimensional vector including numerical and one-
hot encoded categorical clinical features.
• End-Stage Renal Disease (ESRD) Dataset We perform
the mortality risk prediction on an end-stage renal disease
dataset. There are many people suffered from ESRD in the
world [18, 37]. They face severe life threat and need lifelong
treatment with periodic visits to the hospitals for multifari-
ous tests (e.g., blood routine examination). The whole proce-
dure needs a dynamic risk prediction system to help patients
prevent adverse outcomes, based on the medical records col-
lected along with the visits. The cleaned dataset consists of
656 patients and 13,091 visit records and the percentage of
positive labels is 17.5%. The raw data includes 17 numeric
physiologic variables at each timestep. During and after data
collection and analysis, the authors could not identify indi-
vidual participants as patients’ names were replaced by ID.
We use patients’ previous records to fill the missing data in
order to prevent the leakage of future information.
4.2 Baselines
We evaluated StageNet against the following baselines, which
share some of the similar insights with StageNet. It is worth not-
ing that there are lots of state-of-the-art clinical prediction models
which utilize attention mechanism to extract long-term dependen-
cies in patients’ historical visits [4, 24, 34]. However, their contri-
bution is orthogonal to ours. We focus on capturing and utilizing
stage information of patients’ health status in EHR data. Our model
StageNet can be easily combined with attention mechanism.
• LSTM [12] The visit input at the t-th timestep is fed into the
LSTM model. Then it directly output the prediction results
based on the hidden state vector ht .
• ON-LSTM [33] uses LSTM to model tree-like structures for
natural language sequences by separately allocating hidden
state dimensions with long and short-term information.
• T-LSTM [2] handles visit-level irregular time intervals by
enabling time decay inside RNN cell, which makes older
information less important. The original T-LSTM model is
used for unsupervised clustering, and we modify it into a
supervised learning model.
• Decay-LSTM [43] uses feature-level time intervals to en-
able memory decay similar to T-LSTM. We adopt the decay
mechanism on the input gate of LSTM. Decay-LSTM requires
to input time intervals of each feature, and we also input this
information to all the other models without loss of fairness.
• Health-ATM− [26] uses irregular time intervals to decay
the information from historical timestep via a hybrid CRNN
structure. The original model utilizes the target-aware at-
tention mechanism to achieve disease prediction. Since our
task doesn’t have a specific target embedding to guide the
attention, we remove the target-aware attention mechanism
from Health-ATM.
We also compare StageNet against its reduced models:
• StageNet-I consists of regular LSTM and the stage-adaptive
convolutional module. The weighted convolution operation
is also replaced by regular convolution operation. We use the
average of ht within the observation window to calculate
zt .
• StageNet-II only has stage-aware LSTM. The visit input at
the t-th timestep is fed into the stage-aware LSTM model.
Then it directly outputs the prediction results based on the
hidden state vector ht .
4.3 Health Risk Prediction
In this section, we report experimental results for following super-
vised tasks on two datasets.
• Decompensation risk predictionWe perform the physi-
ologic decompensation prediction task on MIMIC-III dataset.
This task involves the detection of patients who are physio-
logically decompensating, which means conditions are de-
teriorating rapidly. Detection of decompensation is closely
related to problems like condition monitoring and sepsis
detection that have received significant attention from the
machine learning community. The task is formulated as a
binary classification task for predicting whether the patient’s
date of death (DOD) falls within the next 24 hours of the
current time point. These labels are assigned to each hour,
starting at four hours after admission to the ICU and ending
when the patient dies or is discharged.
We truncate the length of samples to a reasonable limit (i.e.
400). We fix a test set of 15% of patients, and divide the
rest of the dataset into the training set and validation set
with a proportion of 85%:15%. We fix the best model on the
validation set and report the performance in the test set.
We also report the standard deviation of the performance
measures by bootstrapping the results on the test set for
10,000 times.
• Mortality risk predictionWe perform the mortality risk
prediction task on the ESRD dataset. Similar to the decompen-
sation task, the mortality risk prediction task is formulated
as a binary classification task to predict whether the patient
will die within 12 months, and the predictions are made at
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Table 2: Performance comparison on MIMIC-III and ESRD dataset
MIMIC-III ESRD
Model AUPRC AUROC min(Re, P+) AUPRC AUROC min(Re, P+)
Baseline
LSTM 0.280 (0.003) 0.897 (0.002) 0.324 (0.003) 0.270 (0.029) 0.805 (0.026) 0.318 (0.015)
ON-LSTM 0.304 (0.002) 0.895 (0.003) 0.343 (0.004) 0.291 (0.021) 0.810 (0.021) 0.333 (0.034)
T-LSTM 0.282 (0.004) 0.895 (0.002) 0.322 (0.005) 0.276 (0.027) 0.812 (0.026) 0.331 (0.031)
Decay-LSTM 0.294 (0.002) 0.893 (0.003) 0.330 (0.004) 0.289 (0.020) 0.808 (0.022) 0.328 (0.021)
Health-ATM− 0.291 (0.002) 0.897 (0.003) 0.325 (0.003) 0.287 (0.021) 0.810 (0.039) 0.331 (0.025)
Reduced StageNet-I 0.313 (0.003) 0.899 (0.003) 0.360 (0.002) 0.296 (0.014) 0.814 (0.031) 0.333 (0.018)
Model StageNet-II 0.311 (0.003) 0.897 (0.002) 0.358 (0.003) 0.302 (0.029) 0.812 (0.027) 0.334 (0.017)
Proposed StageNet 0.323 (0.002) 0.903 (0.002) 0.372 (0.003) 0.327 (0.022) 0.821 (0.024) 0.352 (0.019)
each timestep. We evaluate the models with 10-fold cross-
validation strategy and report the average performance and
standard deviations.
Implementation DetailsWe train each model for 50 epochs on
MIMIC-III dataset and 200 epochs on the ESRD dataset. The learn-
ing rate is set to 0.001. All methods are implemented in PyTorch 1.1
[27] and trained on a server equipped with an Intel Xeon E5-2620
Octa-Core CPU, 256GB Memory and a Titan V GPU.
Evaluation Metrics Following existing works[15, 26, 34], we as-
sess performance using area under the receiver operating char-
acteristic curve (AUROC), area under the precision-recall curve
(AUPRC), and the minimum of precision and sensitivity Min(Re,P+).
The Min(Re,P+) is calculated as the maximum of min(recall, preci-
sion) on the precision-recall curve.
4.3.1 Results. Table 2 compares the performance of all models
on both datasets. StageNet consistently outperforms all state-of-
the-art models on both datasets. On MIMIC-III dataset, StageNet
achieves 10% higher AUPRC and min(Re,P+) compared to the best
baseline model ON-LSTM and Health-ATM. On the ESRD dataset,
StageNet achieves 12% higher AUPRC and 6% higher min(Re, P+)
compared to the best baseline model ON-LSTM.
The reduced models StageNet-I and StageNet-II still outper-
form all state-of-the-art models in most cases on both datasets.
It proves that extracting higher-level temporal variation features
and summarizing stage information are both helpful for predicting
patients’ health risks. Among all baselines, ON-LSTM and Health-
ATM achieve better performance in most cases due to handling the
aforementioned challenges to some extent.
4.3.2 Observations.
Health status stability vs. Cause of death In order to under-
stand how different clinical events affect disease progression, we
further analyze the health status stability of patients with different
causes of death in the ESRD dataset. At each timestep, StageNet
will output a scalar st , which indicates the variation of patients’
stage. A large st indicates the patient’s current health status has
changed a lot compared to history status (i.e. enter a new stage).
We compute the average stage variation (i.e. the average of st ) for
each patient. A patient with stable health status will have a low
st . The average stage variation of patients with different causes of
death is shown in Fig. 5.
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Figure 5: Causes of death and status stability
The result shows that patients who died of peritonitis, cardiovas-
cular (CVD) and cerebrovascular (CVE) have the highest st , which
means that their health status are very unstable. These diseases are
acute diseases and have high mortality rate [7, 9, 21]. The health sta-
tus of patients who have these diseases tends to deteriorate rapidly
in a short period of time, which explains why our model believes
these patients’ status are highly unstable. In contrast, patients with
cancer have the most stable status compared to other patients, since
their health status often deteriorates more chronically and have
longer survival time compared to the patients with acute cardiac
diseases [5, 32]. Clinicians should pay more attention to patients
with heart disease or peritonitis history in order to take timely
interventions.
Health status stability vs. Health risk. The stability of patients’
health status is an important indicator to evaluate patients’ health
risk [13, 31, 42]. At each visit, our model will evaluate the patient’s
current health status and output a health risk score. We divide
patients’ visits into three groups according to predicted health risk:
Low risk (risk score <= 0.4), Medium risk (0.4 < risk score <= 0.7)
and High risk (risk score >= 0.7). We compute the average stage
variation of each group to explore Table 3.
The results show that the health status of patients with high risk
is more unstable, and patients with low risk have the most stable
status. This is consistent with conclusions in medical researches
that clinicians use physiologic stability index to evaluate patients’
health risk (i.e. patients with unstable status have higher mortality
risk) [13, 42].
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Table 3: Health risk levels and status stability
Risk level Low risk Medium risk High risk
Avg. stage var. 0.354 (0.003) 0.393 (0.003) 0.437 (0.005)
4.3.3 Case study. To explore how our model extracts the stage
variation information of patients’ health status and further utilize
it to make predictions, we present a specific case study of a patient
in the test set. As shown in Figure 6, the purple line indicates the
stage variation st and the red line is the predicted mortality risk yt
of the patient.
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Figure 6: Case study
For this specific patient, there is a distinct rising period in the
two lines. Before May 2011, the patient’s risk remains within a
relatively low range. At the same time, st also keeps a low value,
which indicates that the model believes that the patient’s health
status is stable during this time. However, around 2012, the stage
variation reaches the peak and the predicted risk rises rapidly,
which means the patient has entered a high-risk stage. The risk
remains a high value until the end. According to the clinical notes,
the patient encountered Acute Myocardial Infarction (AMI) around
2012, and eventually died because of heart disease. If physicians
were reminded when the model found the patient’s status was
changing drastically, the adverse outcome may be prevented or
delayed by taking early interventions.
4.4 Patient Subtyping
In this experiment, we conduct patient subtyping on the ESRD
dataset to investigate the expressive power of the patient represen-
tation learned from the StageNet. ESRD is a chronic disease, and
patients need to receive continuous medical treatment for years
or even decades. Patients may face various risk factors such as
infection, heart disease or cancer [41]. Patient subtyping task is to
seek patient groups with similar disease progression pathways [2].
Identifying patients subtypes can help clinicians develop targeted
treatment plans and prevent adverse outcomes.
We use the learned u˜t at the last timestep in the previous risk
prediction task as representations for patients’ health status. For
baseline models, we use the representations before the output layer.
The learned representations are used to cluster the patients by the
k-means algorithm [14]. Since we do not know the ground truth
groups of subtypes, we conduct several statistical analysis to assess
the subtyping performance. Moreover, we use Calinski-Harabasz
score [3] (C-H score for abbreviation) to evaluate the subtyping
performance quantitatively. A higher C-H score relates to a model
with better defined clusters. The C-H score is calculated as:
Calinski-Harabasz score = tr (Bk )
tr(Wk )
m − k
k − 1 (13)
wherem is sample size, k is the number of clusters, Bk is the covari-
ance matrix between clusters,Wk is the covariance matrix within
clusters, and tr is the trace of matrix.
We fix a test set of 20% of patients, and the other 80% of patients
are used for training. We use the same hyper-parameter as the
risk prediction task. We tried several k values for the k-means
algorithm. We can observe four main clusters. Therefore we report
the clustering Calinski-Harabasz score and average groud truth
mortality risk in each cluster when k = 4. The results are shown in
Table 4.
Table 4: Clustering results when k = 4
C-H score Cluster I Cluster II Cluster III Cluster IV
LSTM 74 0.09 0.19 0.33 0.59
ON-LSTM 104 0.08 0.20 0.25 0.48
T-LSTM 31 0.03 0.08 0.09 0.85
Decay-LSTM 43 0.08 0.23 0.24 0.54
Health-ATM− 81 0.07 0.23 0.28 0.47
StageNet 165 0.05 0.06 0.60 0.69
The results show StageNet achieves over 58% higher Calinski-
Harabasz score compared to the best baseline model Health-ATM−.
The average risk in each cluster shows that StageNet divide pa-
tients into two high-risk groups (Cluster III and IV) and two low-risk
groups (Cluster I and II). On-LSTM, Decay-LSTM andHealth-ATM−
divide patients into one high-risk group (Cluster IV), two medium-
risk groups (Cluster II and III) and one low-risk group (Cluster I).
However, T-LSTM only identifies one high-risk group (Cluster IV)
and three low-risk groups (Cluster I, II and III). Risk scores of differ-
ent clusters for our baseline models are increasing evenly, which
means the learned representations distribute evenly in latent space
and not form meaningful clusters and thus results in low C-H score.
4.4.1 High-risk patient subtypes. In order to interpret the cluster-
ing results in terms of subtyping, we compared the medium-risk
and high-risk clusters with low-risk clusters using T-test to iden-
tify discriminative features (p-value < 0.05). We find that there are
5-7 significant features in each cluster, and we report the top 5
significant features ranked by p-value in Table 5.
The results show that almost all baseline models choose albumin,
C-reactive protein, glucose, chlorine, diastolic blood pressure and
blood urea to distinguish between low-risk patients and high-risk
patients. However, significant features in different high-risk and
medium-risk clusters are almost the same for all baseline models,
which indicates that these models are unable to further distinguish
subtypes among high-risk patients and therefore have worse clus-
tering performance.
In contrast, StageNet clearly divides patients into two high-risk
groups and also identifies more discriminative features. In Cluster
III, albumin, blood urea and appetite are important indicators related
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Table 5: Most significant features (ranked by p-value) in
medium-risk and high-risk clusters.
LSTM
Cluster II Albumin C-rp Blood chlorineDBP Glucose
Cluster III Albumin C-rp Blood chlorineGlucose DBP
Cluster IV Albumin C-rp DBPSerum creatinine Glucose
ON-LSTM
Cluster II Albumin Glucose C-rpBlood urea DBP
Cluster III Albumin Glucose DBPBlood urea C-rp
Cluster IV Albumin DBP C-rpGlucose Blood urea
T-LSTM
Cluster IV Albumin Blood chlorine Serum creatinineBlood potassium DBP
Decay-LSTM
Cluster II DBP Albumin Blood chlorinehs-CRP Blood sodium
Cluster III Albumin DBP Blood chlorineGlucose hs-CRP
Cluster IV DBP Blood chlorine Albuminhs-CRP Glucose
Health-ATM
Cluster II Blood chlorine Blood potassium AlbuminDBP Blood urea
Cluster III Blood chlorine Albumin Blood potassiumDBP Blood urea
Cluster IV Blood chlorine Blood potassium AlbuminDBP Glucose
StageNet
Cluster III Albumin Serum creatinine Blood ureaAppetite C-rp
Cluster IV C-rp DBP Blood potassiumAlbumin Hemoglobin
to patients’ nutritional status [6, 11, 28]. These biomarkers can
reflect patients’ health status from a long-term perspective. While
in Cluster IV, blood potassium and diastolic blood pressure are
important indicators for heart diseases such as heart failure [21, 23].
Patients with high white blood cell count and C-reactive protein are
likely to have severe infections [8, 19].We also notice that StageNet
identifies hemoglobin as a significant feature in Cluster IV, which
has never been identified by other baseline models. According to
medical research, the constant reducing of hemoglobin is a key
factor denoting the occurrence of acute GI bleeding [38], which
may cause sudden death.
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Figure 7: Cause of death distribution for StageNet results:
The distribution of two clusters are very different, which
leads to distinct phenotypes
We also explore the distribution of cause of death in Cluster
III and Cluster IV of StageNet, the result is shown in Fig 7. In
Cluster III, the main causes of death are cancer and gastrointestinal
disease (GI disease), which are mainly considered as more chronic
disease [5, 32]. While in Cluster IV, the main causes of death are
cardiovascular, peritonitis and cerebrovascular, which are acute
symptoms [7, 9, 21]. This is consistent with medical researches
and our previous experiment results. However, baseline models
failed to identify these high-risk subtypes. For example, the cause
of death distribution for ON-LSTM is shown in Fig 8. There is no
significant difference in the cause of death distribution between
different clusters.
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Figure 8: Cause of death distribution for ON-LSTM results:
Distribution of different clusters are very similar, which
means lower quality of clusters
4.4.2 Low-risk patient subtypes. In Table 4, StageNet also divides
low-risk patients into two subtypes (Cluster I and II). To identify the
difference between the two clusters, we report the discriminative
features in two clusters using T-test and the mean value of these
features in each cluster. The result is shown in Table 6.
We can observe that patients in Cluster I have higher serum
creatinine, glucose, blood chlorine and lower albumin compared
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Table 6: Significant features (ranked by p-value) in Cluster I
andCluster II of StageNet results. Even two low-risk clusters
have quite different range of lab measures.
Feature Cluster I Mean Cluster II Mean
Serum creatinine 988.1 (172.4) 758.3 (112.8)
Glucose 6.9 (1.4) 5.4 (1.0)
Albumin 36.7 (3.2) 40.9 (2.5)
Blood chlorine 100.1 (2.9) 97.5 (2.1)
to patients in Cluster II. As discussed above, albumin and serum
creatinine are important indicators for patients’ nutritional status,
and indicate the severity of patientsâĂŹ ESRD progression [6, 28].
Kidney damage may cause high blood chlorine level and high glu-
cose level may indicate patients have diabetes [1]. In conclusion,
patients in Cluster I have higher potential health risk compared to
patients in Cluster II.
4.4.3 Health status stability vs. Patient subtypes. In order to un-
derstand how patients’ disease progression stage information help
StageNet to identify patient subtypes, we calculate the average
stage variation of patients in each cluster. The results are shown in
Table 7
Table 7: Patient subtypes and status stability
Cluster I II III IV
Avg. stage var. 0.297 (0.044) 0.295 (0.039) 0.350 (0.038) 0.409 (0.031)
The results show that the variation of patients’ health status
is positively correlated with patients’ health risk in each cluster,
which have been proved in Table 3. We notice that patients in
Cluster IV have the most unstable status, since they have more
acute symptoms. Though patients in Cluster III still have high
health risk, they have lower stage variation compared to Cluster IV,
because their disease progressions are more chronic. The results in
Table 7 are consistent with the observations and medical findings
we discussed above. Compared to baseline models, StageNet can
learn discriminative patient representations from EHR sequences by
extracting and utilizing the disease progression stage information.
5 CONCLUSIONS
In this work, we propose a stage-aware neural network model,
StageNet, to conduct health risk prediction using patients’ stage
variation of health status. StageNet consists of a stage-aware LSTM
module and a stage-adaptive convolutional module. StageNet can
extract the stage of patients’ health status at each visit unsupervis-
edly, then leverage and re-calibrate stage-related variation patterns
into risk prediction. Supervised health risk prediction experiments
on two real-world datasets demonstrate that StageNet consistently
outperforms state-of-the-art methods by better capturing inherent
disease progression stage information in EHR data. Compared to
the best baseline model, StageNet achieves 10% higher AUPRC and
min(Re,P+) on public MIMIC-III dataset, and 12% higher AURPC
and 6% higher min(Re,P+) on ESRD dataset. The patient subtyping
experiment shows that StageNet performs better than baseline
models to learn discriminative representations by extracting and
utilizing the stage information. In clinical practice, we hope our
model can help physicians identify the patients with unstable health
status to prevent or delay the adverse outcome.
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A DATASET DETAILS
The basic statistics of two dataset are shown in Table 8.
Table 8: Basic Statistics of ESRD and MIMIC Dataset
Statistic Value
ESRD
# patients 656
# patients died 261
# visit 13091
# visit with positive label (yt = 1) 2287
# visit with negative label (yt = 0) 10804
# average time interval between visits 3.4 months
% female 49%
MIMIC-III
# patients 33,678
# ICU stays 41,902
# visit 2,202,114
# visit with positive label (yt = 1) 45,364
# visit with negative label (yt = 0) 2,156,750
% female 44%
B IMPLEMENTATION DETAILS
For hyper-parameter settings of each baseline model, our principle
is as follows: For some hyper-parameter, we will use the recom-
mended setting if it is available in the original paper. Otherwise,
we determine its value by grid search on the validation set.
• LSTM/T-LSTM/Decay-LSTM. The hidden units of LSTM
cell are set to 64 / 128 for ESRD / MIMIC-III dataset respec-
tively.
• ON-LSTM. The hidden units of LSTM cell are set to 72 /
384. The chunk size factor C is set to 36 / 128 for ESRD /
MIMIC-III dataset respectively.
• Health-ATM−. The hidden units of LSTM cell are set to 64 /
128. The number of convolutional filters is set to 32 / 64 and
the size of filters is set to 3 / 5 for ESRD / MIMIC-III dataset
respectively.
• StageNet. The length of observation window K is set to 10.
The hidden units of LSTM cell are set to 72 / 384. The chunk
size factor C is set to 36 / 128.
Additionally, we use dropout [35] before the output layer and
dropconnect [39] in the LSTM layer. The dropout rate is set to 0.5 /
0.3 for ESRD / MIMIC-III dataset respectively. We train each model
for 50 epochs on MIMIC-III dataset and 200 epochs on the ESRD
dataset. The learning rate is set to 0.001.
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